Cabergoline Improves Metabolic Status in Hyperprolactinemia
A single-center, observational study suggests that 6 months of treatment with the dopamine agonist cabergoline improves cardiometabolic measures in patients with a prolactinoma and hyperprolactinemia.
First Look
source https://www.medscape.com/viewarticle/974577?src=rss
First Look
source https://www.medscape.com/viewarticle/974577?src=rss
Comments
Post a Comment